HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
The company had recorded adjusted earnings of 75 cents per share in the year-ago period. Total revenues in the third quarter increased 34% year over year to $290 million. Revenues surpassed the Zacks Consensus Estimate of $248 million. The top line was primarily driven by higher royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab) as well as an increase in milestone revenues during the quarter. Based on the strong performance so far this year, Halozyme raised its 2024 financial guidance. Shares of Halozyme were up 14.7% in after-hours trading on Oct. 31 owing to the better-than-expected results and the increase in guidance. The stock has rallied 36.8% in the year-to-date period against the industry's decline of 3.6%. Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Halozyme's top line comprises product sales, royalties and revenues under collaborative agreements
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsPR Newswire
- Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.MarketBeat
- HALO vs. FOLD: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 10/31/24 - Beat
HALO
Sec Filings
- 11/12/24 - Form SC
- 10/31/24 - Form 10-Q
- 10/31/24 - Form 8-K
- HALO's page on the SEC website